PLoS ONE:两种蛋白质FKBP12和FKBP12.6调节心脏细胞内钙的释放

2012-03-09 MedSci MedSci原创

近日,PLoS ONE发表了英国布里斯托大学和曼彻斯特大学研究人员的成果,揭开了心力衰竭的机制,发现两种蛋白质调节心脏细胞内钙的释放,为避免这种风险情况提供了新的可能。 心力衰竭患者由于心脏细胞中钙离子未得到正确控制并因此而引发的不规则心跳,从而面临着意外死亡的风险。这项研究由布里斯托尔大学生理与药理学院的研究人员完成,他们揭示了两种独立却极其相似的蛋白质共同调节心脏细胞中钙离子浓度的机制以及这

近日,PLoS ONE发表了英国布里斯托大学和曼彻斯特大学研究人员的成果,揭开了心力衰竭的机制,发现两种蛋白质调节心脏细胞内钙的释放,为避免这种风险情况提供了新的可能。

心力衰竭患者由于心脏细胞中钙离子未得到正确控制并因此而引发的不规则心跳,从而面临着意外死亡的风险。这项研究由布里斯托尔大学生理与药理学院的研究人员完成,他们揭示了两种独立却极其相似的蛋白质共同调节心脏细胞中钙离子浓度的机制以及这种双重调节方式在心力衰竭中的减弱方式。

在健康人的心脏细胞中,钙离子从细胞内的储存中释放出来并形成心脏的有力跳动,从而将血液泵至全身。钙离子通过叫做“兰尼碱受体(RyR)通道”的特定通路在恰当的时间以合适的量进行释放。而在心力衰竭患者中,细胞内的钙释放会变得没有规律,从而导致心跳节奏异常。

通过将单独的RyR通道从心脏细胞中移除并整合至人工膜中,研究人员对流经单个通道分子的微量钙离子流进行了测定。他们发现,两种分别称为FKBP12和FKBP12.6的蛋白质紧密地结合在RyR通道上,并改变着流经它们的钙离子的量。

他们的研究显示,FKBP12与FKBP12.6蛋白非常相似,但是在功能上完全不同。FKBP12增加通过RyR的钙离子流,而FKBP12.6起着阻碍FKBP12这种效果的作用。在心力衰竭患者中,这种双重调节似乎遭受了破坏。

该校的Rebecca Sitsapesan博士说:“心脏及循环系统疾病是英国人口死亡的一个主要原因,每年造成大约191000人死亡,是总死亡人数的三分之一。这些新的发现非常重要,因为我们可以利用这些信息为心力衰竭患者开发新的疗法,以减少意外死亡的风险。”

来源:http://www.news-medical.net/news/20120223/Dual-regulation-by-similar-proteins-may-degenerate-in-heart-failure.aspx

doi:10.1371/journal.pone.0031956
FKBP12 Activates the Cardiac Ryanodine Receptor Ca2+-Release Channel and Is Antagonised by FKBP12.6

Elena Galfré, Samantha J. Pitt, Elisa Venturi, Mano Sitsapesan, Nathan R. Zaccai, Krasimira Tsaneva-Atanasova, Stephen O'Neill, Rebecca Sitsapesan

Changes in FKBP12.6 binding to cardiac ryanodine receptors (RyR2) are implicated in mediating disturbances in Ca2+-homeostasis in heart failure but there is controversy over the functional effects of FKBP12.6 on RyR2 channel gating. We have therefore investigated the effects of FKBP12.6 and another structurally similar molecule, FKBP12, which is far more abundant in heart, on the gating of single sheep RyR2 channels incorporated into planar phospholipid bilayers and on spontaneous waves of Ca2+-induced Ca2+-release in rat isolated permeabilised cardiac cells. We demonstrate that FKBP12 is a high affinity activator of RyR2, sensitising the channel to cytosolic Ca2+, whereas FKBP12.6 has very low efficacy, but can antagonise the effects of FKBP12. Mathematical modelling of the data shows the importance of the relative concentrations of FKBP12 and FKBP12.6 in determining RyR2 activity. Consistent with the single-channel results, physiological concentrations of FKBP12 (3 µM) increased Ca2+-wave frequency and decreased the SR Ca2+-content in cardiac cells. FKBP12.6, itself, had no effect on wave frequency but antagonised the effects of FKBP12.

We provide a biophysical analysis of the mechanisms by which FK-binding proteins can regulate RyR2 single-channel gating. Our data indicate that FKBP12, in addition to FKBP12.6, may be important in regulating RyR2 function in the heart. In heart failure, it is possible that an alteration in the dual regulation of RyR2 by FKBP12 and FKBP12.6 may occur. This could contribute towards a higher RyR2 open probability, ‘leaky’ RyR2 channels and Ca2+-dependent arrhythmias.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1765466, encodeId=5f061e6546614, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 22 06:03:00 CST 2013, time=2013-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789383, encodeId=dca91e89383dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Jul 25 21:03:00 CST 2012, time=2012-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296844, encodeId=0d43129684423, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Mar 11 13:03:00 CST 2012, time=2012-03-11, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1765466, encodeId=5f061e6546614, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 22 06:03:00 CST 2013, time=2013-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789383, encodeId=dca91e89383dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Jul 25 21:03:00 CST 2012, time=2012-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296844, encodeId=0d43129684423, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Mar 11 13:03:00 CST 2012, time=2012-03-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1765466, encodeId=5f061e6546614, content=<a href='/topic/show?id=252ae1803a3' target=_blank style='color:#2F92EE;'>#白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71803, encryptionId=252ae1803a3, topicName=白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Fri Feb 22 06:03:00 CST 2013, time=2013-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789383, encodeId=dca91e89383dd, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Jul 25 21:03:00 CST 2012, time=2012-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1296844, encodeId=0d43129684423, content=<a href='/topic/show?id=158288e017c' target=_blank style='color:#2F92EE;'>#蛋白质#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88701, encryptionId=158288e017c, topicName=蛋白质)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Sun Mar 11 13:03:00 CST 2012, time=2012-03-11, status=1, ipAttribution=)]